Division of Clinical Research, Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, MO.
Division of Clinical Research, Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, MO.
Am J Obstet Gynecol. 2014 Mar;210(3):210.e1-5. doi: 10.1016/j.ajog.2013.11.023. Epub 2013 Nov 16.
The objective of the study was to evaluate the prevalence of medical contraindications in a large group of women seeking combined hormonal contraception (CHC).
The Contraceptive CHOICE Project is a prospective cohort study designed to promote the use of long-acting reversible contraceptive methods to reduce unintended pregnancies in the St Louis region. During baseline enrollment, participants were asked about their desired methods of contraception and medical history. Potential medical contraindications were defined as self-reported history of hypertension, myocardial infarction, cerebral vascular accidents, migraines with aura, any migraine and age 35 years or older, smoking in women older than 35 years, venous thromboembolism, or liver disease. We reviewed all research charts of women with self-reported medical contraindications to verify all conditions. Binomial 95% confidence intervals (CIs) were calculated around percentages.
Between August 2007 and December 2009, 5087 women who enrolled in the CHOICE Project provided information about their medical history and 1010 women (19.9%) desired CHC at baseline. Seventy women (6.93%; 95% CI, 5.44-8.68%) were defined as having a potential medical contraindication to CHC at baseline. After chart review, only 24 of 1010 participants desiring CHC (2.38%; 95% CI, 1.53-3.52%) were found to have true medical contraindications to CHC including 17 with hypertension, 2 with migraines with aura, 2 with a history of venous thromboembolism, and 3 smokers aged 35 years or older.
The prevalence of medical contraindications to CHC was very low in this large sample of reproductive-aged women. This low prevalence supports provision of CHC without a prescription.
本研究旨在评估大量寻求复方激素避孕(CHC)的女性中存在的医学禁忌证的流行情况。
避孕选择项目(CHOICE Project)是一项前瞻性队列研究,旨在推广使用长效可逆避孕方法,以减少圣路易斯地区的非意愿妊娠。在基线入组时,参与者被问及他们希望使用的避孕方法和病史。潜在的医学禁忌证被定义为自我报告的高血压、心肌梗死、脑血管意外、有先兆的偏头痛、任何偏头痛和年龄 35 岁或以上、35 岁以上吸烟的女性、静脉血栓栓塞或肝脏疾病史。我们审查了所有有自我报告医学禁忌证的女性的研究记录,以验证所有条件。围绕百分比计算了二项式 95%置信区间(CI)。
2007 年 8 月至 2009 年 12 月,5087 名参加 CHOICE 项目的女性提供了有关其病史的信息,其中 1010 名女性(19.9%)在基线时希望使用 CHC。70 名女性(6.93%;95%CI,5.44-8.68%)在基线时被定义为存在 CHC 的潜在医学禁忌证。经记录审查,只有 1010 名希望使用 CHC 的参与者中有 24 名(2.38%;95%CI,1.53-3.52%)被发现真正存在 CHC 的医学禁忌证,包括 17 名高血压患者、2 名有先兆偏头痛患者、2 名静脉血栓栓塞史患者和 3 名 35 岁或以上的吸烟者。
在这个大量生殖年龄女性的样本中,CHC 的医学禁忌证的流行率非常低。这种低流行率支持在没有处方的情况下提供 CHC。